Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S, Soerjomataram I. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast. 2022;66:15–23. https://doi.org/10.1016/j.breast.2022.08.010.

Article  PubMed  PubMed Central  Google Scholar 

Balamou C, Koïvogui A, Rymzhanova R, Cornelis S, Rodrigue-Moulinie C, Sellier N. Breast cancer incidence by age at discovery of mammographic abnormality in women participating in French organized screening campaigns. Public Health. 2022;202:121–30. https://doi.org/10.1016/j.puhe.2021.11.012.

Article  PubMed  CAS  Google Scholar 

Weigelt B, Geyer FC, Reis-Filho JS. Histological types of breast cancer: how special are they? Mol Oncol. 2010;4(3):192–208. https://doi.org/10.1016/j.molonc.2010.04.004.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ferreira Almeida C, Correia-da-Silva G, Teixeira N, Amaral C. Influence of tumor microenvironment on the different breast cancer subtypes and applied therapies. Biochem Pharmacol. 2024;223:116178. https://doi.org/10.1016/j.bcp.2024.116178.

Article  PubMed  CAS  Google Scholar 

Jiang J, Li L, Yin G, Luo H, Li J. A molecular typing method for invasive breast cancer by serum Raman spectroscopy. Clin Breast Cancer. 2024. https://doi.org/10.1016/j.clbc.2024.02.008

Article  PubMed  Google Scholar 

Dri A, Arpino G, Bianchini G, Curigliano G, Danesi R, De Laurentiis M, Del Mastro L, Fabi A, Generali D, Gennari A, Guarneri V, Santini D, Simoncini E, Zamagni C, Puglisi F. Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs). Cancer Treat Rev. 2024;123:102672. https://doi.org/10.1016/j.ctrv.2023.102672.

Article  PubMed  CAS  Google Scholar 

Keskinkilic M, Sacks R. Antibody-Drug conjugates in triple negative breast cancer. Clin Breast Cancer. 2024;24(3):163–74. https://doi.org/10.1016/j.clbc.2024.01.008. https://doi.org/https://doi.org/.

Article  PubMed  CAS  Google Scholar 

Izci H, Punie K, Waumans L, Laenen A, Wildiers H, Verdoodt F, Desmedt C, Ardui J, Smeets A, Han SN, Nevelsteen I, Neven P, Floris G. Correlation of TROP-2 expression with clinical–pathological characteristics and outcome in triple-negative breast cancer. Sci Rep. 2022;12(1):22498. https://doi.org/10.1038/s41598-022-27093-y.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Narayana RVL, Gupta R. Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatment. Oncogene. 2025;44(28):2343–56. https://doi.org/10.1038/s41388-025-03448-3.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Qiu S, Zhang J, Wang Z, Lan H, Hou J, Zhang N, et al. Targeting Trop-2 in cancer: recent research progress and clinical application. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2023;1878(4):188902. https://doi.org/10.1016/j.bbcan.2023.188902.

Article  PubMed  CAS  Google Scholar 

Dernbach G, Eich M-L, Dragomir MP, Anders P, Jurczok N, Stief C, et al. Spatial expression of HER2, NECTIN4, and TROP-2 in muscle-invasive bladder cancer and metastases: implications for pathological and clinical management. Mod Pathol. 2025;38(7):100753. https://doi.org/10.1016/j.modpat.2025.100753.

Article  PubMed  Google Scholar 

Parisi C, Mahjoubi L, Gazzah A, Barlesi F. TROP-2 directed antibody-drug conjugates (ADCs): the revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC). Cancer Treat Rev. 2023;118:102572. https://doi.org/10.1016/j.ctrv.2023.102572.

Article  PubMed  CAS  Google Scholar 

Chiba Y, Kojima Y, Yazaki S, Yoshida H, Takamizawa S, Kitadai R, Saito A, Okuma HS, Nishikawa T, Shimoi T, Sudo K, Noguchi E, Uno M, Ishikawa M, Kato T, Fujiwara Y, Yonemori K. Trop-2 expression and the tumor immune microenvironment in cervical cancer. Gynecol Oncol. 2024;187:51–7. https://doi.org/10.1016/j.ygyno.2024.04.022.

Article  PubMed  CAS  Google Scholar 

Cheng M, Li X, Li Y, Wang Y, Li W, Wang S, et al. LBA and LC-MS/MS based comprehensive bioanalytical methods for FDA018, a Trop-2 targeted antibody-drug conjugate. J Pharm Biomed Anal. 2025;264:116964. https://doi.org/10.1016/j.jpba.2025.116964.

Article  PubMed  CAS  Google Scholar 

Zeng P, Chen M-B, Zhou L-N, Tang M, Liu C-Y, Lu P-H. Impact of TROP2 expression on prognosis in solid tumors: a systematic review and meta-analysis. Sci Rep. 2016;6(1):33658. https://doi.org/10.1038/srep33658.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kalinsky K, Diamond JR, Vahdat LT, Tolaney SM, Juric D, O’Shaughnessy J, et al. Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial. Ann Oncol. 2020;31(12):1709–18. https://doi.org/10.1016/j.annonc.2020.09.004.

Article  PubMed  CAS  Google Scholar 

Gu Y, Wang Z, Wang Y. Bispecific antibody drug conjugates: making 1 + 1 > 2. Acta Pharm Sinica B. 2024;14(5):1965–86. https://doi.org/10.1016/j.apsb.2024.01.009. https://doi.org/https://doi.org/.

Article  CAS  Google Scholar 

Gadaleta-Caldarola G, Lanotte L, Infusino S, Gadaleta-Caldarola A, Schipilliti FM, Citrigno C, Petrarota C, Cusmai A, Rizzo A. Safety evaluation of Datopotamab Deruxtecan for triple-negative breast cancer: a meta-analysis. Cancer Treat Res Commun. 2023;37:100775. https://doi.org/10.1016/j.ctarc.2023.100775.

Article  PubMed  Google Scholar 

Bardia A, Hurvitz Sara A, Tolaney Sara M, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai Sagar D, Kalinsky K, Zelnak Amelia B, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O’Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey Lisa A, Gianni L, Piccart Martine J, Loibl S, Goldenberg David M, Hong Q, Olivo Martin S, Itri Loretta M. Rugo Hope, sacituzumab Govitecan in metastatic Triple-Negative breast Cancer, new England. J Med. 2021;384(16):1529–41. https://doi.org/10.1056/NEJMoa2028485.

Article  CAS  Google Scholar 

Ocean AJ, Starodub AN, Bardia A, Vahdat LT, Isakoff SJ, Guarino M, Messersmith WA, Picozzi VJ, Mayer IA, Wegener WA, Maliakal P, Govindan SV, Sharkey RM, Goldenberg DM. Sacituzumab Govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics. Cancer. 2017;123(19):3843–54. https://doi.org/10.1002/cncr.30789.

Article  PubMed  CAS  Google Scholar 

Spring LM, Tolaney SM, Fell G, Bossuyt V, Abelman RO, Wu B, Maheswaran S, Trippa L, Comander A, Mulvey T, McLaughlin S, Ryan P, Ryan L, Abraham E, Rosenstock A, Garrido-Castro AC, Lynce F, Moy B, Isakoff SJ, Tung N, Mittendorf EA, Ellisen LW, Bardia A. Response-guided neoadjuvant sacituzumab Govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial☆. Ann Oncol. 2024;35(3):293–301. https://doi.org/10.1016/j.annonc.2023.11.018.

Article  PubMed  CAS  Google Scholar 

Rugo HS, Bardia A, Marmé F, Cortés J, Schmid P, Loirat D, Trédan O, Ciruelos E, Dalenc F, Gómez Pardo P, Jhaveri KL, Delaney R, Valdez T, Wang H, Motwani M, Yoon OK, Verret W, Tolaney SM. Overall survival with sacituzumab Govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402(10411):1423–33. https://doi.org/10.1016/S0140-6736(23)01245-X.

Article  PubMed  CAS  Google Scholar 

Carey LA, Loirat D, Punie K, Bardia A, Diéras V, Dalenc F, Diamond JR, Fontaine C, Wang G, Rugo HS, Hurvitz SA, Kalinsky K, O’Shaughnessy J, Loibl S, Gianni L, Piccart M, Zhu Y, Delaney R, Phan S, Cortés J. Sacituzumab Govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis. Npj Breast Cancer. 2022;8(1):72. https://doi.org/10.1038/s41523-022-00439-5.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Pavone G, Motta L, Martorana F, Motta G, Vigneri P. A new kid on the block: sacituzumab Govitecan for the treatment of breast cancer and. Molecules: Other Solid Tumors; 2021.

Google Scholar 

Reike MJ, Bahlburg H, Brehmer M, Berg S, Noldus J, Roghmann F, et al. Side effects of drug-antibody conjugates enfortumab-vedotin and sacituzumab-govitecan in targeted therapy in cancer. Cancer Epidemiol. 2024;90:102574. https://doi.org/10.1016/j.canep.2024.102574.

Article  PubMed  Google Scholar 

Criscitiello C, Morganti S, Curigliano G. Antibody–drug conjugates in solid tumors: a look into novel targets. J Hematol Oncol. 2021;14(1):20. https://doi.org/10.1186/s13045-021-01035-z.